Mechanistic and Clinical Differences Between Daratumumab and Isatuximab in Multiple Myeloma: Emerging Roles of 1q Gain and Immune Remodeling
Jiro Kikuchi, Hiroshi Yasui · 2026
Read Mechanistic and Clinical Differences Between Daratumumab and Isatuximab in Multiple Myeloma: Emerging Roles of 1q Gain and Immune Remodeling by Jiro Kikuchi, Hiroshi Yasui (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13465549.txt.
Description
Jiro Kikuchi and Hiroshi Yasui compare two CD38 antibodies for multiple myeloma, daratumumab and isatuximab, and argue they are not interchangeable. Both hit the same surface target, yet their grip points and side talents differ. The review assembles mechanism studies and clinic patterns side by side.
Isatuximab clamps the target's enzyme mouth, killing partly through oxidative bursts and a growth switch shutdown. A chromosome gain common in myeloma may mark tumors that answer it best. Daratumumab leans on immune muscle, stripping target levels and loosening drug resistance glue. Each drug also reshapes leftover disease and the immune scene differently. Picking by tumor biology, the authors propose, beats picking by habit.
Catalog record
| CREATOR | Jiro Kikuchi, Hiroshi Yasui |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45375 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |